Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
The radiotracer [(11)C]N-desmethyl-loperamide (dLop) images the in vivo function of P-glycoprotein (P-gp), a transporter that blocks the entry of drugs that are substrates into brain. When P-gp is inhibited, [(11)C]dLop, a potent opiate agonist, enters and becomes trapped in the brain. This trapping is beneficial from an imaging perspective, because it amplifies the PET signal, essentially by accumulating radioactivity over time. As we previously demonstrated that this trapping was not caused by binding to opiate receptors, we examined whether [(11)C]dLop, a weak base, is ionically trapped in acidic lysosomes. To test this hypothesis, we measured [(3)H]dLop accumulation in human cells by using lysosomotropics. Because the in vivo trapping of dLop was seen after P-gp inhibition, we also measured [(3)H]dLop uptake in P-gp-expressing cells treated with the P-gp inhibitor tariquidar. All lysosomotropics decreased [(3)H]dLop accumulation by at least 50%. In P-gp-expressing cells, tariquidar (and another P-gp inhibitor) surprisingly decreased [(3)H]dLop uptake. Consequently, we measured [(11)C]dLop uptake before and after tariquidar preadministration in lysosome-rich organs of P-gp KO mice and humans. After tariquidar pretreatment in both species, radioactivity uptake in these organs decreased by 35% to 40%. Our results indicate that dLop is trapped in lysosomes and that tariquidar competes with dLop for lysosomal accumulation in vitro and in vivo. Although tariquidar and dLop compete for lysosomal trapping in the periphery, such competition does not occur in brain because tariquidar has negligible entry into brain. In summary, tariquidar and [(11)C]dLop can be used in combination to selectively measure the function of P-gp at the blood-brain barrier.
Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA.
Pavitra
P
Kannan
Kyle R
KR
Brimacombe
William C
WC
Kreisl
Jeih-San
JS
Liow
Sami S
SS
Zoghbi
Sanjay
S
Telu
Yi
Y
Zhang
Victor W
VW
Pike
Christer
C
Halldin
Michael M
MM
Gottesman
Robert B
RB
Innis
Matthew D
MD
Hall
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D001812:Blood-Brain Barrier / Q000000981:diagnostic imaging / Q000378:metabolism; D045744:Cell Line, Tumor; D006801:Humans; D007553:Isotope Labeling / Q000379:methods; D008139:Loperamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D008247:Lysosomes / Q000378:metabolism*; D051379:Mice; D049268:Positron-Emission Tomography / Q000379:methods*; D011804:Quinolines / Q000494:pharmacology; D011859:Radiography; D014316:Tritium / Q000494:pharmacology*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D011804:Quinolines; C419149:N-demethylloperamide; D014316:Tritium; D008139:Loperamide; C402343:tariquidar
Mol Cancer Ther. 2008 Sep;7(9):3081-91
18790787
Ann Nucl Med. 2010 Jun;24(5):403-12
20361276
Biopharm Drug Dispos. 1988 Nov-Dec;9(6):513-26
3067757
Biochemistry. 1996 Mar 5;35(9):2811-7
8608115
Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59
17428165
Biochem Pharmacol. 1974 Sep 15;23(18):2495-531
4606365
J Histochem Cytochem. 1997 Sep;45(9):1255-64
9283613
Pharmacogenetics. 2002 Oct;12(7):535-41
12360104
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4432-7
10200279
J Pharm Sci. 2007 Apr;96(4):729-46
17117426
Br J Cancer. 2006 Mar 27;94(6):884-90
16495920
J Pharmacol Exp Ther. 2010 Apr;333(1):120-8
20056778
J Med Chem. 2008 Oct 9;51(19):6034-43
18783208
Nat Rev Cancer. 2002 Jan;2(1):48-58
11902585
J Nucl Med. 2005 Feb;46(2):354-64
15695797
Cancer Res. 1986 Nov;46(11):5941-6
3756931
J Nucl Med. 2006 Sep;47(9):1531-7
16954563
Bioorg Med Chem. 2010 Aug 1;18(15):5489-97
20621487
J Biochem. 1994 Feb;115(2):213-8
8206870
J Nucl Med. 2010 Apr;51(4):559-66
20237038
J Biol Chem. 2006 Sep 8;281(36):26501-11
16844693
Cell Immunol. 1985 Jul;93(2):486-96
4005959
Int J Oncol. 2007 Sep;31(3):473-84
17671672
J Nucl Med. 2008 Apr;49(4):649-56
18344435
J Nucl Med. 2009 Jan;50(1):108-15
19091890
Clin Pharmacol Ther. 2009 Oct;86(4):368-77
19625998
Prog Neurobiol. 2005 May;76(1):22-76
16011870
Br J Cancer. 2008 May 20;98(10):1597-601
18475291
ACS Chem Neurosci. 2011 Feb 16;2(2):82-9
22778859
Drug Metab Dispos. 2010 Jun;38(6):917-22
20212014
Curr Top Med Chem. 2010;10(17):1834-45
20645914
Br J Cancer. 1998;77(3):353-8
9472628